June 14, 2017 - Los Angeles - Red Herring today announced the winners of its Top 100 North America 2017 event, recognizing the continent’s most exciting and innovative private technology companies. MiNDERA is among the award recipients.
The winners, celebrated at a special awards ceremony at the Marina Del Rey Marriott Hotel, have been chosen from thousands of entrants, whittled down to hundreds making the trip to California. The ceremony, led by Red Herring chairman Alex Vieux, was preceded by two days of keynote speeches, discussions and finalist presentations.
Companies were judged by industry experts, insiders and journalists on a wide variety of criteria including financial performance, innovation, business strategy and market penetration. Winners ran the gamut of verticals, from fintech and marketing to security, IoT and many more.
May 25, 2017 - Philippe Nore, Chief Executive Officer, will be representing MiNDERA at the French-American Business Awards dinner in San Francisco on May 25. MiNDERA is nominated in the Life Sciences and Biotech category.
MiNDERA to present first clinical data at SID 2017
April 27, 2017 - Dr Tobin Dickerson, MiNDERA’s Chief Scientific Officer, will be presenting new data regarding non-invasive transcriptome extraction from the skin using MiNDERA’s microneedle technology at the 2017 Annual Meeting of the Society for Investigative Dermatology in Portland on April 28 and 29. These data demonstrate the successful application of MiNDERA microneedle devices to human subjects and subsequent analysis by qPCR and RNA-Seq. Excellent correlation was observed between the mRNA extracted by the MiNDERA device and biopsy.
Poster Title: Non-invasive skin transcriptome extraction using MiNDERA microneedle technology
Poster number: LB968
Friday, April 28 from 11:30 AM - 1:30 PM
Hall A-A1 of the Oregon Convention Center
Saturday, April 29, 2017
10:45 – 11:45 am
MiNDERA's core patent issued in the US
January 26, 2017 - We are pleased to announce that the patent covering our core intellectual property has been issued this month by the USPTO. This patent (9,540,684) is an important step towards building a broad and high-value IP portfolio.
January 21, 2017 - MiNDERA will be present at the Personalized Medicine World Conference. We are hoping to see you there. The conference will be held January 23-25 at the Computer History Museum in Mountain View, CA.
June 13, 2016 - MiNDERA is selected as a Rosenman Innovation Awards finalist and will be showcased at the 2016 Rosenman Symposium "Medical Devices Reimagined" on Wednesday, June 22nd, 2016 from 1:00 to 5:30 pm at the Byers Auditorium, UCSF Mission Bay.
April 8, 2016 - MiNDERA has been selected as one of the emerging companies that will present at the BIOVISION Investor Conference to be held on April 13 and 14 2016 in Lyon, France.
Biovision World Life Science Forum is fostering a unique approach to meet,connect and collaborate between international decision-makers from the academic, civil society, policy-making and private sectors whether industrials or investors. The Investor Conference accelerates the fundraising process of Biotech, Medtech, e-health and environmental health start-ups by putting them in direct contact with potential business and development partners. Selected from a pool of applicants by a special committee, start-ups with the greatest potential to offer innovative health solutions will present their pitches during the BIOVISION forum in front of a jury comprised of leading European private and corporate investors in the life sciences.
March 31, 2016 - We are pleased to announce that MiNDERA has been selected as one of the 10 emerging companies that will present at the BioSciKin competition for life sciences start-ups on April 7, 2016 at Stanford University in Palo Alto, CA.
Nanjing BioSciKin Co., Ltd (BSK), an open investment and incubation platform in China for life science innovation is sponsoring thisinternational startup contest in life science. The co-sponsors include influential Chinese industrial investors, pharmaceutical companies and Chinese media with the support of a powerful alliance of strategic investors. The event runs from December 2015 to June 2016. It will take place in 8 cities in both China and the US, where the US preliminaries will be held in San Francisco and Boston. The final competition will be in Shanghai.
January 14, 2016 - Our CEO Philippe Nore will be presenting at the Personalized Medicine World Conference on January 25 at 1:15pm Pacific Time. The conference will be held January 25-27 at the Computer History Museum in Mountain View, CA.
October 27, 2015 - We are delighted to announce that MiNDERA won the 2015 QB3 Diagnostics Startup of the Year Award. Thanks to our team members, advisors, collaborators and investors for their contribution and support. We are honored to receive this prestigious award.
October 19, 2015 - Our CEO Philippe Nore will be presenting at the 14th Annual BIO Investor Forum tomorrow at 1:30pm Pacific Time. The conference will be held October 20-21 at the Parc 55 San Francisco.
October 12, 2015 - MiNDERA Corp. (“MiNDERA), a leader in non-invasive molecular diagnostics for dermatology and skin-related cancers, announced today the close of its $1 million Seed financing round. Scientific Health Development and other individual investors are among MiNDERA’s new investors. This financing round will enable MINDERA to further validate its proprietary micro-needle technology and prepare for the launch of its first research products.
October 5, 2015 - MiNDERA will be exhibiting at the 2015 AdvaMed Conference in San Diego on October 6 and 7. Please stop by our booth in the Innovation Pavilion to find out more about our technology if you are also attending. Our CEO, Philippe Nore, and our scientific founder, Dr Tobin Dickerson are attending the conference and are looking forward to meeting customers and partners.
SAN FRANCISCO, March 3, 2015 /PRNewswire/ -- Johnson & Johnson Innovation LLC today announced the opening of JLABS @South San Francisco (JLABS @SSF), a 30,000-square foot incubator located at 329 Oyster Point Boulevard, South San Francisco, Calif. The Johnson & Johnson Innovation, JLABS (JLABS) site can accommodate up to 50 startups from across the healthcare spectrum including biotech, pharmaceutical, medical device, consumer and digital health.